Biblio
Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica. 2023.
Autologous Transplantation for Male Germ Cell Tumors: Improved Outcomes over 3 decades. Biol Blood Marrow Transplant. 2019.
Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Blood Adv. 2019;3(20):3123-3131.
CIBMTR Chronic GVHD Risk Score Predicts Mortality in an Independent Validation Cohort. Biol Blood Marrow Transplant. 2014.
Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. J Clin Oncol. 2020:JCO1900396.
CSRP2 transcript levels after consolidation therapy increase prognostic prediction ability in B-cell acute lymphoblastic leukaemia. Biomol Biomed. 2023.
External validation of the predictive scoring systems for molecular responses in chronic myeloid leukaemia receiving initial imatinib-therapy. Leukemia. 2023.
. Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improves Transplant Outcomes in Older MDS Patients. Transplant Cell Ther. 2021.
Glucose partitioning in the bone marrow micro-environment in acute myeloid leukaemia. Leukemia. 2023.
. Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma. J Clin Oncol. 2013.
Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase. Am J Hematol. 2023.
Inferior Outcomes with Cyclosporine and Mycophenolate mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019.
Methodological challenges in the development of endpoints for myelofibrosis clinical trials. Lancet Haematol. 2024.
Molecular monitoring of tyrosine kinase inhibitor therapy of chronic myeloid leukemia in China. J Cancer Res Clin Oncol. 2016.
. Mutations in DEAD/H-box helicase 11 correlate with increased relapse risk in adults with acute myeloid leukaemia with normal cytogenetics. Leukemia. 2023.
Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate, but not High Disease Risk Index: A CIBMTR Study: Superior DFS with MAC comp. Biol Blood Marrow Transplant. 2020.
Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Biol Blood Marrow Transplant. 2018.
Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation. Biol Blood Marrow Transplant. 2014.
Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow allografts have improved Long-term Overall and Graft-versus-Host Disease, Relapse-Free Survival. Biol Blood Marrow Transplant. 2018.
A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Myelodysplastic Syndromes Patients. Biol Blood Marrow Transplant. 2020.
. .